162 related articles for article (PubMed ID: 24015398)
21. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.
Fortunak JM; de Souza RO; Kulkarni AA; King CL; Ellison T; Miranda LS
Antivir Ther; 2014; 19 Suppl 3(0 3):15-29. PubMed ID: 25310430
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of generic antiretroviral therapy.
Hirnschall G; de Joncheere C
Ann Intern Med; 2013 May; 158(10):776. PubMed ID: 23689769
[No Abstract] [Full Text] [Related]
23. Cost-effectiveness of generic antiretroviral therapy--in response.
Walensky RP; Paltiel AD; Schackman BR
Ann Intern Med; 2013 May; 158(10):776-7. PubMed ID: 23689770
[No Abstract] [Full Text] [Related]
24. Global fund decides to promote use of generic drugs.
Elliott R
Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):58-9. PubMed ID: 14740604
[No Abstract] [Full Text] [Related]
25. Working together to provide generics for health.
Beck EJ; Reiss P
Antivir Ther; 2014; 19 Suppl 3():1. PubMed ID: 25310234
[No Abstract] [Full Text] [Related]
26. Kenya says yes to generic ARVs but fails to win Global Fund cash.
Njoroge J
Bull World Health Organ; 2002; 80(7):608. PubMed ID: 12163933
[No Abstract] [Full Text] [Related]
27. [Declining costs].
Neumaier J
MMW Fortschr Med; 2016 Jun; 158 Suppl 1():58. PubMed ID: 27259908
[No Abstract] [Full Text] [Related]
28. World Trade Organization still threatens supply of affordable AIDS drugs.
Hagmann M
Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
[No Abstract] [Full Text] [Related]
29. The discovery and development of antiretroviral agents.
Lange JM; Ananworanich J
Antivir Ther; 2014; 19 Suppl 3():5-14. PubMed ID: 25310317
[TBL] [Abstract][Full Text] [Related]
30. Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reduction.
Ramiro MA; Llibre JM
Enferm Infecc Microbiol Clin; 2014 Nov; 32(9):598-602. PubMed ID: 24139337
[TBL] [Abstract][Full Text] [Related]
31. [The patent legislation in India fails the HIV/AIDS work].
Holen Ø
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2666-7. PubMed ID: 16215618
[No Abstract] [Full Text] [Related]
32. Desimplification of Single Tablet Antiretroviral (ART) Regimens-A Practical Cost-Savings Strategy?
Krentz H; Campbell S; Gill J
J Int Assoc Provid AIDS Care; 2019; 18():2325958218822304. PubMed ID: 30672364
[TBL] [Abstract][Full Text] [Related]
33. The impact of visa status and Medicare eligibility on people diagnosed with HIV in Western Australia: a qualitative report.
Herrmann S; Wardrop J; John M; Gaudieri S; Lucas M; Mallal S; Nolan D
Sex Health; 2012 Nov; 9(5):407-13. PubMed ID: 22950904
[TBL] [Abstract][Full Text] [Related]
34. Production of low cost AIDS drugs to continue in Brazil.
Reprod Health Matters; 2001 Nov; 9(18):178. PubMed ID: 11803899
[No Abstract] [Full Text] [Related]
35. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
[TBL] [Abstract][Full Text] [Related]
36. Affordable drug access for developing countries.
Highleyman L
BETA; 2001; 14(2):12-25. PubMed ID: 11785481
[No Abstract] [Full Text] [Related]
37. Treating and Preventing HIV with Generic Drugs - Barriers in the United States.
Martin EG; Schackman BR
N Engl J Med; 2018 Jan; 378(4):316-319. PubMed ID: 29365306
[No Abstract] [Full Text] [Related]
38. Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction.
Rwagitinywa J; Sommet A; Palmaro A; Montastruc JL; Lapeyre-Mestre M
Health Policy; 2018 Mar; 122(3):237-242. PubMed ID: 29398158
[TBL] [Abstract][Full Text] [Related]
39. Intellectual property rights, market competition and access to affordable antiretrovirals.
Pascual F
Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
[TBL] [Abstract][Full Text] [Related]
40. Physicians say generic AIDS drugs don't threaten R&D.
AIDS Policy Law; 2002 Mar; 17(6):4. PubMed ID: 12004757
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
